查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1917890

个人化医疗市场－2026-2031年预测

Personalized Medicine Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计个人化医疗市场将从 2025 年的 4,636.8 亿美元成长到 2031 年的 7,673.8 亿美元，复合年增长率为 8.76%。

个人化医疗市场代表着医疗保健领域的一次根本性转变，它摒弃了「一刀切」的模式，转而采用以数据为导向的精准诊断、治疗和预防方法。这种模式整合了基因、分子、环境和生活方式讯息，从而根据每位患者的独特特征量身定制医疗决策和干预措施。在多种技术整合的推动下，该市场正透过改善治疗效果、减少不利事件和优化医疗资源，彻底改变从肿瘤学到心臟病学的各个治疗领域。基因组学的突破、诊断能力的提升以及製药和诊断行业的策略调整，是推动其成长的主要动力。

该市场的核心技术驱动力是基因组学和多体学技术的持续进步。蛋白质体学、代谢体学和转录组学的成熟，以及基因测序成本和时间的快速下降，为表征个体分子特征提供了前所未有的能力。这种深入的生物学洞察能够识别特定的生物标记（例如基因突变、蛋白质表现和代谢特征），从而预测疾病感受性、预后和治疗反应。基于这些分子驱动因素的患者分层是精准医疗的基础原则，它推动了标靶治疗和诊断方法的开发与应用。

推动临床应用的重要因素之一是药物基因体学的发展。药物基因体学研究个别基因组成对药物反应的影响。透过识别影响药物代谢、疗效和毒性的基因变异，临床医生可以在治疗开始前优化药物选择和剂量。这种方法已被证实能够显着减少处方中的试验误过程，降低药物不良反应的发生率，并改善治疗效果。随着其临床效用和成本效益的证据不断积累，药物基因组学正日益融入标准治疗方案和药物研发流程，巩固其在个人化医疗生态系统中的地位。

随着治疗方法的进步，个人化诊断和伴随诊断也不断发展并日益成熟。市场正从单基因检测向复杂的多重分析检测和能够同时分析数百个基因组标靶的次世代定序平台转型。伴随诊断，即与特定治疗产品使用直接相关的检测，如今已成为许多标靶癌症疗法获得监管和商业认可的先决条件。这些诊断技术的开发对于识别最有可能从特定药物中获益的患者亚群至关重要，从而确保治疗惠及合适的患者，最大限度地提高临床获益，并提升高成本特药的价值提案。

竞争与合作并存是该市场的显着特征。成功的个人化医疗需要传统上各自独立的学科之间进行深度整合。这促使製药公司、诊断开发商、技术/平台提供者和数据分析公司之间建立了大量的策略联盟和伙伴关係。製药公司利用这些合作，从药物发现和开发的早期阶段就将生物标记策略纳入其中，而诊断公司则能够接触到治疗管线和临床检验路径。这些协同效应使得研究成果能够快速转化为临床可操作的工具和治疗方法，从而缩短开发週期，并提高获得监管和商业成功的可能性。

从地理上看，北美保持着主导地位，这得益于多种因素的共同作用，包括强大的生物技术和製药行业、公共和私人对基因组研究的大量投资、相对有利的新型诊断和标靶治疗法规环境，以及支持先进检测的高额医疗保健支出。该地区完善的临床试验基础设施，加上日益重视以价值为导向的医疗保健模式（该模式奖励治疗效果的改善），进一步巩固了其作为个性化医疗创新主导培养箱和早期采用者的地位。

这个市场涵盖了广泛的价值链，从支援分析的技术平台（例如次世代定序仪和高通量仪器）到诊断测试开发商、解读复杂数据的生物资讯公司，再到开发客製化标靶治疗的治疗开发商。主要产业参与者在这条价值链的多个环节中竞争与合作，而定序技术领导企业则提供支撑整个产业发展的关键工具。

总之，个人化医疗市场正从一个充满前景的概念发展成为现代生物医学研究和临床照护的核心组织原则。其成长轨迹与生物学知​​识的持续扩展、运算能力的不断提升以及资料整合能力的不断发展密不可分。未来的发展将受到许多挑战的影响，例如检测标准化、为复杂诊断建立清晰的报销机制、临床医生教育的需求以及基因数据的伦理管理。然而，凭藉其改善患者预后的显着能力以及更有效地指导高成本治疗的经济必要性，个人化医疗必将继续重新定义不断扩展的频谱的护理标准，使医疗保健更具预测性、预防性和精准性。

本报告的主要优势：

  • 深入分析：获得主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
  • 市场驱动因素与未来趋势：探索推动市场的动态因素和关键趋势，以及它们将如何塑造未来的市场发展。
  • 可操作的建议：利用这些见解，在动态环境中製定策略决策，发展新的业务流和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

您打算如何使用这份报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议
  • 正在研发中的产品

第四章 技术展望

第五章：按类型分類的个人化医疗市场

  • 介绍
  • 药物基因组学
  • 生物标誌物
  • 精准治疗
  • 其他的

第六章：按应用分類的个人化医疗市场

  • 介绍
  • 肿瘤学
  • 循环系统
  • 感染疾病
  • 神经病学
  • 其他的

第七章：按最终用户分類的个人化医疗市场

  • 介绍
  • 医院和诊所
  • 诊断中心
  • 其他的

第八章：按地区分類的个人化医疗市场

  • 介绍
  • 北美洲
    • 按类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 按类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 德国
      • 法国
      • 英国
      • 西班牙
      • 义大利
      • 其他的
  • 中东和非洲
    • 按类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 按类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 印尼
      • 泰国
      • 台湾
      • 其他的

第九章：竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Novartis Ag
  • Pfizer Inc.
  • Merck KgaA
  • Astrazeneca Plc
  • Bristol Myers Squibb Company
  • Amgen Inc.
  • Guardant Health Inc
  • Caris Life Sciences
  • Thermo Fisher Scientific Inc.

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615955

Personalized Medicine Market, with a 8.76% CAGR, is anticipated to reach USD 767.383 billion in 2031 from USD 463.680 billion in 2025.

The personalized medicine market represents a fundamental shift in healthcare, moving away from a one-size-fits-all model towards a targeted, data-driven approach to diagnosis, treatment, and prevention. This paradigm tailors medical decisions and interventions to the individual characteristics of each patient, integrating genetic, molecular, environmental, and lifestyle information. Enabled by converging technological advancements, the market is revolutionizing therapeutic areas from oncology to cardiology by improving treatment efficacy, minimizing adverse events, and optimizing healthcare resource utilization. Its growth is propelled by breakthroughs in genomic science, the expansion of diagnostic capabilities, and strategic realignments across the pharmaceutical and diagnostic industries.

The core technological driver of this market is the continuous advancement in genomics and multi-omics technologies. The precipitous decline in the cost and time of genomic sequencing, coupled with the maturation of proteomics, metabolomics, and transcriptomics, has unlocked unprecedented ability to characterize an individual's molecular profile. This deep biological insight allows for the identification of specific biomarkers-genetic mutations, protein expressions, or metabolic signatures-that can predict disease susceptibility, prognosis, and response to therapy. The ability to stratify patients based on these molecular drivers is the foundational principle of personalized medicine, enabling the development and application of targeted therapeutics and diagnostics.

A critical application driving clinical adoption is the growth of pharmacogenomics-the study of how an individual's genetic makeup affects their response to drugs. By identifying genetic variants that influence drug metabolism, efficacy, and toxicity, clinicians can optimize medication selection and dosing before treatment begins. This approach demonstrably reduces the trial-and-error process in prescribing, decreases the incidence of adverse drug reactions, and improves therapeutic outcomes. As evidence of its clinical utility and cost-effectiveness accumulates, pharmacogenomics is becoming increasingly integrated into standard care pathways and drug development processes, solidifying its role within the personalized medicine ecosystem.

Parallel to therapeutic advances is the expansion and sophistication of personalized diagnostics and companion diagnostics. The market is moving beyond single-gene tests to complex multi-analyte assays and next-generation sequencing panels that can interrogate hundreds of genomic targets simultaneously. Companion diagnostics, which are tests specifically linked to the use of a corresponding therapeutic product, are now a regulatory and commercial prerequisite for many targeted cancer therapies. The development of these diagnostics is essential for identifying the patient subpopulation most likely to benefit from a specific drug, thereby ensuring treatment is delivered to the right patient, maximizing clinical benefit and supporting the value proposition of high-cost specialty pharmaceuticals.

The competitive and collaborative landscape is a defining feature of the market. Success in personalized medicine requires deep integration across traditionally separate domains. This has led to a surge in strategic collaborations and partnerships between pharmaceutical companies, diagnostic developers, technology/platform providers, and data analytics firms. Pharmaceutical companies leverage these alliances to embed biomarker strategies early in drug development, while diagnostic companies gain access to therapeutic pipelines and clinical validation pathways. These synergies are accelerating the translation of research into clinically actionable tools and treatments, reducing development timelines and improving the probability of regulatory and commercial success.

Geographically, North America maintains a leading position, driven by a confluence of factors. These include a robust biotechnology and pharmaceutical sector, substantial public and private investment in genomic research, a relatively favorable regulatory environment for novel diagnostics and targeted therapies, and high healthcare expenditure that can support advanced testing. The region's well-established infrastructure for clinical trials and a growing emphasis on value-based care models that reward improved outcomes further reinforce its role as the primary incubator and early adopter of personalized medicine innovations.

The market encompasses a broad value chain, from the technology platforms enabling analysis-such as next-generation sequencers and high-throughput instrumentation-to the diagnostic test developers, bioinformatics companies interpreting complex data, and the therapeutic developers creating matched targeted drugs. Key industry players often compete and collaborate across multiple points in this chain, with leaders in sequencing technology providing the essential tools that enable the entire field.

In conclusion, the personalized medicine market is transitioning from a promising concept to a central organizing principle of modern biomedical research and clinical care. Its growth trajectory is inextricably linked to the ongoing expansion of biological knowledge, computational power, and data integration capabilities. Future development will be shaped by challenges including the standardization of testing, the establishment of clear reimbursement pathways for complex diagnostics, the need for clinician education, and the ethical management of genetic data. However, the demonstrated ability to improve patient outcomes and the economic imperative to direct costly therapies more efficiently ensure that personalized medicine will continue to redefine standards of care across a growing spectrum of diseases, making healthcare more predictive, preventive, and precise.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Personalized Medicine Market Segmentation

  • By Type
  • Pharmacogenomics
  • Biomarkers
  • Precision Therapeutics
  • Others
  • By Application
  • Oncology
  • Cardiology
  • Infectious Disease
  • Neurology
  • Others
  • By End-User
  • Hospitals & Clinics
  • Diagnostics Centers
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations
  • 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. PERSONALIZED MEDICINE MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Pharmacogenomics
  • 5.3. Biomarkers
  • 5.4. Precision Therapeutics
  • 5.5. Others

6. PERSONALIZED MEDICINE MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Oncology
  • 6.3. Cardiology
  • 6.4. Infectious Disease
  • 6.5. Neurology
  • 6.6. Others

7. PERSONALIZED MEDICINE MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Diagnostics Centers
  • 7.4. Others

8. PERSONALIZED MEDICINE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. United Kingdom
      • 8.4.4.4. Spain
      • 8.4.4.5. Italy
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. India
      • 8.6.4.3. Japan
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Thailand
      • 8.6.4.7. Taiwan
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. F. Hoffmann-La Roche Ltd.
  • 10.2. Illumina, Inc.
  • 10.3. Novartis Ag
  • 10.4. Pfizer Inc.
  • 10.5. Merck KgaA
  • 10.6. Astrazeneca Plc
  • 10.7. Bristol Myers Squibb Company
  • 10.8. Amgen Inc.
  • 10.9. Guardant Health Inc
  • 10.10. Caris Life Sciences
  • 10.11. Thermo Fisher Scientific Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations